Intra-Cellular Therapies, Inc. (ITCI)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025
Company Description
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders.
The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors.
The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Intra-Cellular Therapies, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 860 |
| CEO | Sharon Mates |
Contact Details
Address: 135 Route 202/206, Suite 6 Bedminster, New Jersey 07921 United States | |
| Phone | 646 440 9333 |
| Website | intracellulartherapies.com |
Stock Details
| Ticker Symbol | ITCI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001567514 |
| CUSIP Number | 46116X101 |
| ISIN Number | US46116X1019 |
| Employer ID | 36-4742850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Michael I. Halstead J.D. | President |
| Sanjeev Narula | Executive Vice President, Chief Financial Officer and Treasurer |
| Dr. Suresh K. Durgam M.D. | Executive Vice President and Chief Medical Officer |
| Mark Neumann | Executive Vice President and Chief Commercial Officer |
| Dr. Robert E. Davis Ph.D. | Senior Vice President and Chief Scientific Officer |
| Juan Fernando Sanchez M.D. | Vice President of Corporate Communications and Investor Relations |
| Karen Patruno Sheehy Esq. | Senior Vice President and Chief Compliance Officer |
| John P. Condon | Senior Vice President, General Counsel and Secretary |
| Dr. Michael Olchaskey Pharm.D. | Senior Vice President and Head of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2025 | POSASR | Filing |
| Apr 2, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 2, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 2, 2025 | 8-K | Current Report |
| Apr 2, 2025 | 25-NSE | Filing |